Andrew Cheng Akero Therapeutics, Inc. (AKRO) insider trading activity

AKRO Quotes by TradingView

Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 605,417 shares of AKRO, which is worth approximately $18.9 Million. The most recent transaction as insider was on Dec 16, 2022, when has been sold 8,500 shares (Common Stock) at a price of $0.62 per share, resulting in proceeds of $5,270. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 605K
0.29% 3M change
31.33% 12M change
Total Value Held $18.9 Million

Andrew Cheng Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 16 2022
BUY
Exercise of conversion of derivative security
$5,270 $0.62 p/Share
8,500 Added 2.24%
370,999 Common Stock
Dec 09 2022
BUY
Grant, award, or other acquisition
-
52,351 Added 12.62%
362,499 Common Stock
Dec 01 2022
SELL
Open market or private sale
$460,700 $46.07 p/Share
10,000 Reduced 3.12%
310,148 Common Stock
Dec 01 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.03%
320,148 Common Stock
Nov 01 2022
SELL
Open market or private sale
$432,100 $43.21 p/Share
10,000 Reduced 3.12%
310,148 Common Stock
Nov 01 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.03%
320,148 Common Stock
Oct 03 2022
SELL
Open market or private sale
$335,900 $33.59 p/Share
10,000 Reduced 3.12%
310,148 Common Stock
Oct 03 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.03%
320,148 Common Stock
Sep 13 2022
SELL
Open market or private sale
$1,633,200 $27.22 p/Share
60,000 Reduced 16.21%
310,148 Common Stock
Sep 13 2022
BUY
Exercise of conversion of derivative security
$37,200 $0.62 p/Share
60,000 Added 13.95%
370,148 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$9,251 $8.03 p/Share
1,152 Added 0.37%
310,148 Common Stock
Mar 01 2022
SELL
Open market or private sale
$175,900 $17.59 p/Share
10,000 Reduced 3.13%
308,996 Common Stock
Mar 01 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.04%
318,996 Common Stock
Feb 01 2022
SELL
Open market or private sale
$175,600 $17.56 p/Share
10,000 Reduced 3.13%
308,996 Common Stock
Feb 01 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.04%
318,996 Common Stock
Jan 10 2022
BUY
Exercise of conversion of derivative security
$6,200 $0.62 p/Share
10,000 Added 3.13%
308,996 Common Stock
Jan 03 2022
BUY
Exercise of conversion of derivative security
$32,860 $0.62 p/Share
53,000 Added 14.64%
308,996 Common Stock
Dec 02 2021
SELL
Open market or private sale
$353,150 $20.18 p/Share
17,500 Reduced 6.4%
255,996 Common Stock
Nov 02 2021
SELL
Open market or private sale
$394,975 $22.57 p/Share
17,500 Reduced 6.01%
273,496 Common Stock
Oct 04 2021
SELL
Open market or private sale
$376,950 $21.54 p/Share
17,500 Reduced 5.67%
290,996 Common Stock
Sep 02 2021
SELL
Open market or private sale
$418,075 $23.89 p/Share
17,500 Reduced 5.37%
308,496 Common Stock
Aug 03 2021
SELL
Open market or private sale
$370,125 $21.15 p/Share
17,500 Reduced 5.09%
325,996 Common Stock
Jul 02 2021
SELL
Open market or private sale
$433,650 $24.78 p/Share
17,500 Reduced 4.86%
342,489 Common Stock
Jan 10 2021
SELL
Open market or private sale
$195,500 $19.55 p/Share
10,000 Reduced 3.24%
298,996 Common Stock
Jan 07 2021
BUY
Exercise of conversion of derivative security
$12,400 $0.62 p/Share
20,000 Added 5.22%
362,989 Common Stock

Also insider at

VERA
Vera Therapeutics, Inc. Healthcare
ABUS
Arbutus Biopharma Corp Healthcare
Director
AC

Andrew Cheng

President and CEO
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AKRO